Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Allows Claims Linking Calcium with Hypertension, Colon/Rectal Cancer

This article was originally published in The Tan Sheet

Executive Summary

FDA will allow qualified health claims linking supplemental calcium intake to a decreased risk of hypertension, the agency announces Oct. 12

You may also be interested in...



Calcium Protects Against Adenomas Five Years Later – JNCI Study

Calcium supplementation has a protective effect on risk of colorectal adenoma recurrence for up to five years after subjects stopped taking calcium, according to a study published in the Journal of the National Cancer Institute Jan. 17

Calcium Protects Against Adenomas Five Years Later – JNCI Study

Calcium supplementation has a protective effect on risk of colorectal adenoma recurrence for up to five years after subjects stopped taking calcium, according to a study published in the Journal of the National Cancer Institute Jan. 17

Calcium Protects Against Adenomas Five Years Later – JNCI Study

Calcium supplementation has a protective effect on risk of colorectal adenoma recurrence for up to five years after subjects stopped taking calcium, according to a study published in the Journal of the National Cancer Institute Jan. 17

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS098728

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel